Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells

Cancer Research

Volumn 60, Issue 23, 2000, Pages 6607-6610

  Taylor, M T ^a   Lawson, K R ^a   Ignatenko, N A ^a   Marek, S E ^a   Stringer, D E ^a   Skovan, B A ^a   Gerner, E W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DNA; MESSENGER RNA; PROSTAGLANDIN SYNTHASE; PROTEIN; SULINDAC SULFIDE;

ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

ANIMALS; ANTICARCINOGENIC AGENTS; CACO-2 CELLS; CLONE CELLS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; GENES, RAS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICE; MICE, SCID; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULINDAC; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034541252     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
2. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
3. Aspirin use and reduced risk of fatal colon cancer
4. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
5. NSAID-induced polyp regression in familial adenomatous polyposis patients
6. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
7. The disposition of sulindac in man
8. Chemical and biological studies of indomethacin, sulindac and their analogs
9. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac
10. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
11. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
12. Induction of cyclooxygenase-2 by activated H-ras oncogene in rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway
13. Sulindac sulfide inhibits ras signaling
14. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
15. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis
16. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine
17. Increased protein kinase C α expression in human colonic CaCo-2 cells after insertion of human Ha-ras or polyamoa virus middle T oncogenes
18. Sulindac inhibits activation of the NF-κB pathway
19. Exisulind induction of apoptosis involves guanosine 3', 5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin
20. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
21. Prevalence of ras gene mutations in human colorectal cancers
22. Detection of high incidence of K-ras oncogenes during human colon carcinogenesis
23. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
24. K-ras is an essential gene in the mouse with partial functional overlap with N-ras